Summary & Overview
HCPCS G9202: Positive Hepatitis C Antibody Test
HCPCS Level II code G9202 designates patients with a positive hepatitis C antibody test, signifying prior or possible current exposure to hepatitis C virus. Nationally, accurate capture of this result using a standardized HCPCS Level II code supports public health surveillance, care coordination, and appropriate follow-up diagnostic workflows. This code is relevant across outpatient clinics and clinical laboratories where serologic screening and reporting occur.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical meaning and use cases, typical service settings, and the areas where benchmarks and policy considerations commonly apply—such as billing practices for laboratory result reporting, linkage-to-care workflows after a positive antibody result, and interactions with diagnostic confirmation testing processes.
The publication provides: a concise clinical context for G9202; what organizations and payers typically consider when processing claims with this code; and guidance on where to look for payer-specific coverage and billing rules. Data not available in the input for specific modifiers, taxonomies, ICD-10 pairings, and related codes are noted where applicable.
Billing Code Overview
HCPCS Level II code G9202 indicates patients with a positive hepatitis C antibody test. The service type is laboratory testing / diagnostic result reporting, reflecting identification of prior or current exposure to hepatitis C virus. The typical site of service is clinical laboratory or outpatient clinic where serologic testing and result documentation occur.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient presents to a primary care clinic after routine screening laboratories detect a positive hepatitis C antibody (G9202 indicates a patient with a positive hepatitis C antibody test). The clinical workflow begins with confirmation of the antibody result, discussion of prior risk factors (e.g., prior intravenous drug use, blood transfusion before 1992, high-risk sexual behavior), and ordering of reflex RNA (HCV RNA) to determine active viremia. The patient receives counseling about transmission, baseline laboratory evaluation (liver panel, complete blood count, coagulation studies), and assessment for comorbid conditions (HIV, hepatitis B). If RNA is detectable, referral to a hepatology or infectious disease specialist occurs for staging (transient elastography or fibrosis scoring), treatment discussion, and initiation of direct-acting antiviral therapy. Typical sites of service include outpatient primary care clinics, community health centers, public health screening events, and laboratory facilities performing serologic testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service on the same day | Use when a distinct E/M visit is provided on the same day as specimen collection or counseling related to the positive antibody result |